Skip to main content
. 2018 Jun 26;62(7):e02584-17. doi: 10.1128/AAC.02584-17

TABLE 1.

In vitro activities of ceftazidime-avibactam and comparative agents against baseline Enterobacteriaceae and Pseudomonas aeruginosa clinical isolates for all randomized patientsa

Baseline pathogen and agent (no. of pathogens tested) MIC (mg/liter)
Range MIC50 MIC90
Enterobacteriaceae
    All Enterobacteriaceae (803)
        Ceftazidime-avibactam ≤0.008 to >256 0.12 0.25
        Ceftazidime ≤0.03 to >64 0.12 32
        Amikacin 0.5 to >64 2 4
        Aztreonam ≤0.03 to >64 0.06 64
        Cefepime ≤0.008 to >16 0.03 >16
        Ceftaroline ≤0.008 to >256 0.12 >256
        Ceftriaxone ≤0.015 to >32 0.06 >32
        Gentamicin ≤0.12 to >16 0.5 >16
        Imipenem 0.06 to 16 0.12 0.5
        Levofloxacin 0.008 to >8 0.06 >8
        Meropenem 0.008 to >8 0.015 0.06
        Piperacillin-tazobactam ≤0.06 to >128 2 16
        Tigecycline 0.06 to 9 0.25 1
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 >8
    Citrobacter freundii complex (32)
        Ceftazidime-avibactam 0.03 to 0.5 0.12 0.25
        Ceftazidime 0.12 to >64 0.25 2
        Amikacin 0.5 to 4 1 2
        Aztreonam ≤0.03 to >64 0.12 16
        Cefepime 0.015 to >16 0.03 1
        Ceftaroline 0.06 to >256 0.12 128
        Ceftriaxone 0.03 to >32 0.12 >32
        Gentamicin 0.25 to >16 0.5 0.5
        Imipenem 0.12 to 1 0.25 0.5
        Levofloxacin 0.015 to 8 0.06 0.5
        Meropenem 0.008 to 0.06 0.015 0.03
        Piperacillin-tazobactam 0.5 to >128 2 128
        Tigecycline 0.12 to 2 0.25 0.5
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 ≤0.25
    Enterobacter aerogenes (10)
        Ceftazidime-avibactam 0.12 to 2 0.12 0.5
        Ceftazidime 0.12 to >64 0.12 0.5
        Amikacin 1 to >64 1 2
        Aztreonam ≤0.03 to >64 ≤0.03 0.25
        Cefepime 0.03 to >16 0.03 0.06
        Ceftaroline 0.06 to >256 0.12 0.25
        Ceftriaxone 0.06 to >32 0.06 0.25
        Gentamicin 0.25 to >16 0.5 0.5
        Imipenem 0.12 to 1 0.5 1
        Levofloxacin 0.03 to 0.12 0.06 0.12
        Meropenem 0.015 to 0.06 0.03 0.03
        Piperacillin-tazobactam 1 to >128 4 4
        Tigecycline 0.25 to 1 0.5 0.5
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 0.5
    Enterobacter cloacae (29)
        Ceftazidime-avibactam 0.06 to >256 0.25 2
        Ceftazidime 0.06 to >64 0.5 >64
        Amikacin 1 to >64 1 8
        Aztreonam ≤0.03 to >64 0.12 >64
        Cefepime 0.015 to >16 0.06 >16
        Ceftaroline 0.03 to >256 0.25 >256
        Ceftriaxone ≤0.015 to >32 0.25 >32
        Gentamicin 0.25 to >16 0.5 >16
        Imipenem 0.12 to 8 0.25 0.5
        Levofloxacin 0.03 to >8 0.06 8
        Meropenem 0.015 to >8 0.03 0.5
        Piperacillin-tazobactam 0.5 to >128 4 >128
        Tigecycline 0.5 to 8 0.5 1
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 >8
    Escherichia coli (549)
        Ceftazidime-avibactam ≤0.008 to 4 0.06 0.12
        Ceftazidime ≤0.03 to >64 0.12 8
        Amikacin 0.5 to >64 2 4
        Aztreonam ≤0.03 to >64 0.06 16
        Cefepime ≤0.008 to >16 0.03 16
        Ceftaroline ≤0.008 to >256 0.06 >256
        Ceftriaxone ≤0.015 to >32 0.06 >32
        Gentamicin 0.25 to >16 0.5 >16
        Imipenem 0.06 to 0.5 0.12 0.12
        Levofloxacin 0.008 to >8 0.03 >8
        Meropenem 0.008 to 0.5 0.015 0.03
        Piperacillin-tazobactam ≤0.06 to >128 2 8
        Tigecycline 0.06 to 2 0.25 0.5
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 >8
    Klebsiella oxytoca (32)
        Ceftazidime-avibactam 0.03 to 0.25 0.06 0.12
        Ceftazidime ≤0.03 to 0.25 0.12 0.12
        Amikacin 0.5 to 4 1 1
        Aztreonam ≤0.03 to 1 0.06 0.25
        Cefepime 0.015 to 0.06 0.03 0.03
        Ceftaroline 0.03 to 0.5 0.12 0.25
        Ceftriaxone ≤0.015 to 0.12 0.03 0.06
        Gentamicin ≤0.12 to 1 0.25 0.5
        Imipenem 0.06 to 0.25 0.12 0.25
        Levofloxacin 0.03 to 1 0.06 0.06
        Meropenem 0.015 to 0.03 0.03 0.03
        Piperacillin-tazobactam 0.5 to 4 2 2
        Tigecycline 0.25 to 0.5 0.25 0.5
        Trimethoprim-sulfamethoxazole ≤0.25 to 0.5 ≤0.25 ≤0.25
    Klebsiella pneumoniae (100)
        Ceftazidime-avibactam ≤0.008 to >256 0.12 0.5
        Ceftazidime ≤0.03 to >64 0.12 >64
        Amikacin 0.5 to >64 1 2
        Aztreonam ≤0.03 to >64 ≤0.03 >64
        Cefepime 0.015 to >16 0.03 >16
        Ceftaroline 0.015 to >256 0.12 >256
        Ceftriaxone ≤0.015 to >32 0.06 >32
        Gentamicin ≤0.12 to >16 0.25 >16
        Imipenem 0.06 to 16 0.12 0.25
        Levofloxacin 0.015 to >8 0.06 >8
        Meropenem 0.015 to >8 0.03 0.12
        Piperacillin-tazobactam 0.5 to >128 2 >128
        Tigecycline 0.25 to 4 0.5 2
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 >8
    Proteus mirabilis (17)
        Ceftazidime-avibactam 0.015 to 2 0.03 0.5
        Ceftazidime ≤0.03 to >64 0.06 32
        Amikacin 1 to 16 4 8
        Aztreonam ≤0.03 to 2 ≤0.03 0.5
        Cefepime 0.03 to 2 0.06 1
        Ceftaroline 0.03 to >256 0.06 256
        Ceftriaxone ≤0.015 to >32 ≤0.015 >32
        Gentamicin 0.5 to >16 1 >16
        Imipenem 0.12 to 4 1 4
        Levofloxacin 0.03 to >8 0.12 >8
        Meropenem 0.03 to 0.12 0.06 0.12
        Piperacillin-tazobactam ≤0.06 to 16 0.25 4
        Tigecycline 2 to 8 4 4
        Trimethoprim-sulfamethoxazole ≤0.25 to >8 ≤0.25 >8
Pseudomonas aeruginosa (70)
    Ceftazidime-avibactam 0.5 to 32 2 4
    Ceftazidime 1 to >64 2 8
    Amikacin ≤0.12 to >64 4 8
    Cefepime 0.5 to >16 2 8
    Ceftriaxone 4 to >32 32 >32
    Gentamicin ≤0.12 to >16 1 2
    Imipenem 0.5 to 16 1 2
    Levofloxacin 0.03 to >8 0.5 >8
    Meropenem 0.03 to >8 0.12 2
    Piperacillin-tazobactam 0.5 to >128 4 16
a

Total of 1,066 randomized patients. Some patients had more than one pathogen isolated. Multiple isolates of the same species from the same patient were counted only once using the isolate with the highest MIC to the study drug received. For bacteremic patients, multiple isolates of the same species from the same patient were counted only once using the isolate with the highest MIC to the study drug received across culture source (intra-abdominal site or blood).